Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

NewsGuard 100/100 Score

Abbott (NYSE: ABT) today presented 48-week findings comparing an HIV regimen of its protease inhibitor (PI), Kaletra® (lopinavir/ritonavir), and Merck's integrase inhibitor, Isentress® (raltegravir), to a traditional HIV regimen of Kaletra and the nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) in Truvada® (tenofovir and emtricitabine) in antiretroviral-naive adult patients.  Efficacy data were collected over the first 48 weeks of the 96-week PROGRESS (PROtease/InteGRasE Simplification Study) study.  These data met the primary efficacy endpoint, which measured whether a similar proportion of treatment-naive HIV-infected patients reached undetectable viral loads.  The results were presented at the 28th International AIDS Conference in Vienna, Austria.

"The 48-week PROGRESS study results, while not definitive, suggest that the nucleoside-sparing HIV regimen of Kaletra and Isentress may be an alternative treatment option for patients new to HIV therapy, when compared to a standard HIV regimen.  This further advances our research into new HIV treatment classes and explores the use of alternative drug combinations for patients," said Jacques Reynes, M.D., professor of medicine, head of the Infectious and Tropical Disease Department at the University Hospital Center of Montpellier, France, and a presenting author of the PROGRESS study.

HIV treatment regimens are typically drawn from approximately 20 approved antiretroviral medications in six classes.  Standard regimens for treatment-naive patients generally consist of two NRTIs plus either a PI or a non-nucleoside reverse transcriptase inhibitor (NNRTI).

PROGRESS is a global, multicenter, 96-week open-label study of approximately 200 HIV-infected patients.  Physicians should use caution when interpreting these results of the PROGRESS study.  Key findings through week 48 include:

  • A similar proportion of patients had HIV-1 RNA levels less than 40 copies/mL (defined as undetectable) when treated with Kaletra and Isentress, compared to Kaletra and Truvada.
  • Both groups, on average, had a similar positive immune response, measured by their increase in CD4+ T-cell counts.
  • The safety and tolerability, including incidences of treatment-emergent moderate-to-severe medication-related adverse events, were generally similar between regimens.  Lipid (cholesterol and triglyceride) elevations were observed more frequently in the Kaletra and Isentress group.

"Kaletra is one of the most widely-studied protease inhibitors available, and Abbott believes it is important to look at new ways of combining Kaletra with other HIV medications to explore additional treatment options for patients," said Scott C. Brun, M.D., divisional vice president, infectious disease development, Global Pharmaceutical Research and Development, Abbott.  "The PROGRESS study is another step toward understanding the science behind potential new treatment approaches to help people living with HIV and demonstrates Abbott's continued commitment to HIV research."



The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Immunocompromised patients show prolonged SARS-CoV-2 infection and unique mutations